Company: BDRX
Filing Date: 2025-09-12
Form Type: 424B3
Source: 0001214659-25-013675
Chunk: 20

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-12
Form: 424B3
Chunk 20
---
321,418 |     |           4,063,321 |     |                   4,063,321,418 |     |                 4,063,321 |
| ‘C’ Deferred shares of £0.00005 each                 |     |     126,547,389,518 |     |           6,327,370 |     |                 126,547,389,518 |     |                 6,327,370 |
| ‘D’ Deferred shares of £0.000001 each                |     |   2,482,747,137,178 |     |           2,482,747 |     |                               - |     |                         - |
| Total                                                |     |                     |     |          13,935,391 |     |                                 |     |                11,724,988 |

Ordinary and deferred
shares were recorded as equity.

At a General Meeting
on 11 June 2025, shareholders approved the subdivision and redesignation of the Company’s Issued Ordinary Shares of £0.00005
each into to one Ordinary Share of £0.000001 each and 49 ‘D’ Deferred Shares of £0.000001 each. The ‘D’
Deferred Shares have limited rights and are effectively valueless.

| 19 |

As at June 30, 2025
and December 31, 2024 the Company had 17,415 pre-funded warrants outstanding over ADS’s. These are recognised in the warrant reserve
until exercise.

In accordance with
the Articles of Association for the Company adopted on 11 June 2025, the share capital of the Company consists of an unlimited number
of ordinary shares of nominal value £0.000001 each. Ordinary and deferred shares were recorded as equity.

| 6. | Related party transaction |

The Directors consider
there to be no related party transactions during the periods reported other than Directors Remuneration.

| 7. | Contingent liabilities |

The Company is in
a dispute with a former advisor over fees. In the event the Company is unsuccessful in its dispute the amount due to the vendor is approximately
$1.16 million, of which $0.82 million would be payable in cash and the remainder amount in warrants exercisable for our ADSs. The Directors
note that in the event of an unfavourable resolution the Company would not be able to recoup the loss from another party.

| 8. | Events after the reporting